Last reviewed · How we verify
NCT04312347
Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels
NA trial testing Tamoxifen dose adjustment in ER+ Breast Cancer in 151 participants. Completed in 30 June 2021.
1 May 2021
Quick facts
| Lead sponsor | Nalagenetics Pte Ltd |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 151 |
| Start date | 6 September 2019 |
| Primary completion | 1 May 2021 |
| Estimated completion | 30 June 2021 |
| Sites | 1 location across Indonesia |
Drugs / interventions tested
- Tamoxifen dose adjustment — full drug profile →
Conditions studied
- ER+ Breast Cancer — all drugs for ER+ Breast Cancer →
Sponsor
Nalagenetics Pte Ltd — full company profile →
Who can join
18 and older, female only, with ER+ Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the CYP2D6 genotypes and endoxifen levels.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04312347
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ER+ Breast Cancer
Currently open trials in the same condition.
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07002177 — A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC · Phase 1, PHASE2 · recruiting
- NCT05827614 — Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With · Phase 1 · active not recruiting
- NCT05534438 — A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Appr · Phase 2 · recruiting
- NCT04985266 — A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus · Phase 2 · recruiting
Other Nalagenetics Pte Ltd trials
Trials by the same sponsor.
- NCT05562440 — The Perspective of Healthy Individuals on Breast Cancer Risk Prediction Report In The Indonesian Population · NA · completed
- NCT05504135 — Implementation of Pre-emptive Pharmacogenomics Testing in Singapore-based Private Hospital Institutions (IMPT Study) · completed
- NCT05501158 — CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population · NA · unknown
- NCT05570266 — Genetic and Non-Genetic Breast Cancer Risk Prediction Evaluation in Indonesian Samples · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04312347 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nalagenetics Pte Ltd
- Last refreshed: 5 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04312347.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing